Project Grant R01AI199276
Award Date 9/1/26
Completion Date 8/31/31
Dollars Obligated $838K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, NY 10029, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded Icahn School of Medicine at Mount Sinai $832,773 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to advance an "induce-and-clear" therapeutic strategy targeting HIV-1 latent cellular reservoirs. The research integrates RNA-based latency reversal with engineered high-avidity antibodies to overcome barriers to immune clearance of persistent HIV infection. The project...
- The National Institute of Allergy and Infectious Diseases awarded Icahn School of Medicine at Mount Sinai $840,018 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to define mechanisms by which A35-specific monoclonal antibodies confer protection against monkeypox virus and to characterize qualitative differences in A35-targeted antibody responses elicited by infection versus vaccination. The research addresses inadequacies in current...
- The National Institute of Allergy and Infectious Diseases awarded Icahn School of Medicine at Mount Sinai $156,510 on March 10, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research on how hepatocytes and skeletal myocytes shape immunity to mRNA-lipid nanoparticle-encoded protein. The research addresses off-target mRNA uptake and expression in hepatocytes and skeletal myocytes during mRNA-LNP delivery. The investigator will engineer...
- The National Institute of Allergy and Infectious Diseases awarded Albert Einstein College of Medicine $231,000 on June 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to identify, characterize, and develop human monoclonal antibodies whose primary protective mechanism is antibody-dependent cellular cytotoxicity (ADCC) for treatment and prevention of genital, neonatal, and recurrent herpes simplex virus (HSV) infections. The research builds on preclinical mouse...
- The National Institute of Allergy and Infectious Diseases awarded Icahn School of Medicine at Mount Sinai $209,128 on March 8, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to evaluate differences in innate immune response to highly pathogenic H5N1 viruses. The research tests the hypothesis that different H5N1 isolates exhibit different sensitivity to myxovirus resistance 1 (MX1) protein, a host restriction factor with demonstrated antiviral activity against...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Icahn School of Medicine at Mount Sinai a $3,021,038 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) effective September 2, 2025, with completion targeted for August 31, 2029. This award funds investigator-initiated biomedical research examining the protective role of chemokine receptor CCR5 (C-C Motif Chemokine Receptor 5) in maternal flavivirus...
- The National Institutes of Health Office of the Director awarded Icahn School of Medicine at Mount Sinai $335,999 under the Trans-NIH Research Support program (CFDA 93.310) on September 1, 2026, to generate the first human monoclonal antibodies against anellovirus ORF1 and define the antigenic landscape of this highly prevalent human virus. The award funds research to isolate ORF1-specific memory B cells from donors with detectable serologic responses and generate 50 fully human monoclonal...
- The National Institute of Allergy and Infectious Diseases awarded Icahn School of Medicine at Mount Sinai $100,228 on November 15, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to map HIV reservoir establishment in human tonsil organoids. The research will characterize nonproductively infected cells—those harboring integrated HIV proviruses that express no viral proteins and thus evade clearance by antiviral treatments and the immune system—as a barrier to HIV...
- The National Institute of Allergy and Infectious Diseases, part of the Department of Health and Human Services, awarded Icahn School of Medicine at Mount Sinai $868,915 on September 1, 2026, for Project Grant R01AI193023 under the Allergy and Infectious Diseases Research program (CFDA 93.855). The research investigates the role of ANKEF1, a ciliary protein, in host defense against influenza virus infection. The work combines novel mouse models, human induced pluripotent stem cell-derived...
- The National Institute of Allergy and Infectious Diseases awarded Icahn School of Medicine at Mount Sinai $210,000 on August 7, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) for Project Grant R21AI202288. The project investigates fate-mapping and genetic dissection of B-to-T feedback circuits shaping germinal-center selection. The work examines how transient CD70 expression in germinal-center B cells shapes antibody responses and the fates of both B and T...